SI3665192T1 - Inženiring polipeptidov, ki se vežejo na receptorje za transferine - Google Patents
Inženiring polipeptidov, ki se vežejo na receptorje za transferineInfo
- Publication number
- SI3665192T1 SI3665192T1 SI201830986T SI201830986T SI3665192T1 SI 3665192 T1 SI3665192 T1 SI 3665192T1 SI 201830986 T SI201830986 T SI 201830986T SI 201830986 T SI201830986 T SI 201830986T SI 3665192 T1 SI3665192 T1 SI 3665192T1
- Authority
- SI
- Slovenia
- Prior art keywords
- receptor binding
- transferrin receptor
- binding polypeptides
- engineered transferrin
- engineered
- Prior art date
Links
- 102000007238 Transferrin Receptors Human genes 0.000 title 1
- 108010033576 Transferrin Receptors Proteins 0.000 title 1
- 229920001184 polypeptide Polymers 0.000 title 1
- 102000004196 processed proteins & peptides Human genes 0.000 title 1
- 108090000765 processed proteins & peptides Proteins 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/79—Transferrins, e.g. lactoferrins, ovotransferrins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/40—Transferrins, e.g. lactoferrins, ovotransferrins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A61K47/644—Transferrin, e.g. a lactoferrin or ovotransferrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2881—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD71
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/526—CH3 domain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/77—Internalization into the cell
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2318/00—Antibody mimetics or scaffolds
- C07K2318/20—Antigen-binding scaffold molecules wherein the scaffold is not an immunoglobulin variable region or antibody mimetics
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Toxicology (AREA)
- Neurosurgery (AREA)
- Cell Biology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201762543658P | 2017-08-10 | 2017-08-10 | |
US201762583314P | 2017-11-08 | 2017-11-08 | |
PCT/US2018/018371 WO2018152326A1 (en) | 2017-02-17 | 2018-02-15 | Engineered transferrin receptor binding polypeptides |
PCT/US2018/046199 WO2019032955A1 (en) | 2017-08-10 | 2018-08-10 | MODIFIED TRANSFERRIN RECEPTOR BINDING POLYPEPTIDES |
EP18756531.2A EP3665192B1 (en) | 2017-08-10 | 2018-08-10 | Engineered transferrin receptor binding polypeptides |
Publications (1)
Publication Number | Publication Date |
---|---|
SI3665192T1 true SI3665192T1 (sl) | 2023-11-30 |
Family
ID=65272509
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SI201830986T SI3665192T1 (sl) | 2017-08-10 | 2018-08-10 | Inženiring polipeptidov, ki se vežejo na receptorje za transferine |
Country Status (18)
Country | Link |
---|---|
US (4) | US20200369746A1 (sl) |
EP (2) | EP3665194A4 (sl) |
JP (3) | JP7280241B2 (sl) |
CN (2) | CN111148757A (sl) |
CA (2) | CA3072035A1 (sl) |
DK (1) | DK3665192T3 (sl) |
ES (1) | ES2956062T3 (sl) |
FI (1) | FI3665192T3 (sl) |
HR (1) | HRP20231118T1 (sl) |
HU (1) | HUE063021T2 (sl) |
LT (1) | LT3665192T (sl) |
MD (1) | MD3665192T2 (sl) |
PL (1) | PL3665192T3 (sl) |
PT (1) | PT3665192T (sl) |
RS (1) | RS64584B1 (sl) |
SI (1) | SI3665192T1 (sl) |
TW (1) | TWI821197B (sl) |
WO (2) | WO2019032955A1 (sl) |
Families Citing this family (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
HRP20221505T1 (hr) | 2017-02-17 | 2023-02-17 | Denali Therapeutics Inc. | Proizvedeni polipeptidi za vezanje receptora transferina |
BR112020005271A2 (pt) | 2017-10-02 | 2020-09-15 | Denali Therapeutics Inc. | proteína, polipeptídeo, polinucleotídeo, vetor, célula hospedeira, método para produção de um polipeptídeo, métodos de tratamento de um distúrbio, de diminuição do acúmulo, de monitoramento, de transporte de um agente e de tratamento de um lsd e composição farmacêutica |
PE20230036A1 (es) | 2019-12-23 | 2023-01-10 | Denali Therapeutics Inc | Variantes de progranulina |
EP4090682A1 (en) * | 2020-01-13 | 2022-11-23 | Denali Therapeutics Inc. | Anti-trem2 antibodies and methods of use thereof |
CA3197506A1 (en) | 2020-10-14 | 2022-04-21 | Denali Therapeutics Inc. | Fusion proteins comprising sulfoglucosamine sulfohydrolase enzymes and methods thereof |
US11827702B2 (en) | 2021-09-01 | 2023-11-28 | Biogen Ma Inc. | Anti-transferrin receptor antibodies and uses thereof |
WO2024026488A2 (en) | 2022-07-29 | 2024-02-01 | Regeneron Pharmaceuticals, Inc. | Non-human animals comprising a modified transferrin receptor locus |
WO2024026494A1 (en) | 2022-07-29 | 2024-02-01 | Regeneron Pharmaceuticals, Inc. | Viral particles retargeted to transferrin receptor 1 |
US20240052051A1 (en) | 2022-07-29 | 2024-02-15 | Regeneron Pharmaceuticals, Inc. | Anti-tfr:payload fusions and methods of use thereof |
WO2024026474A1 (en) | 2022-07-29 | 2024-02-01 | Regeneron Pharmaceuticals, Inc. | Compositions and methods for transferrin receptor (tfr)-mediated delivery to the brain and muscle |
Family Cites Families (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2003513016A (ja) * | 1999-08-30 | 2003-04-08 | ニューヨーク・ユニバーシティ | レセプタータンパク質チロシンキナーゼのドメイン、およびそのリガンドの結晶構造 |
ES2354653T3 (es) * | 2006-08-01 | 2011-03-16 | Pieris Ag | Muteínas de lipocalina lacrimal y procedimientos para obtener las mismas. |
ES2631356T3 (es) * | 2010-11-30 | 2017-08-30 | F. Hoffmann-La Roche Ag | Anticuerpos anti-receptor de transferrina de baja afinidad y su uso para transferir scFv terapéuticos a través de la barrera hematoencefálica |
EA201892619A1 (ru) * | 2011-04-29 | 2019-04-30 | Роше Гликарт Аг | Иммуноконъюгаты, содержащие мутантные полипептиды интерлейкина-2 |
SI2890712T1 (sl) * | 2012-08-29 | 2019-08-30 | F. Hoffmann-La Roche Ag | Prenašalec prek krvno-možganske pregrade |
US9708406B2 (en) * | 2013-05-20 | 2017-07-18 | Genentech, Inc. | Anti-transferrin receptor antibodies and methods of use |
MX2016008190A (es) * | 2014-01-06 | 2016-10-21 | Hoffmann La Roche | Modulos de lanzadera de barrera cerebral sanguinea monovalente. |
BR112016027024A2 (pt) * | 2014-05-22 | 2017-10-31 | Pieris Pharmaceuticals Gmbh | polipeptídeos de ligação específica e seus usos |
WO2016077840A2 (en) * | 2014-11-14 | 2016-05-19 | Ossianix, Inc. | TfR SELECTIVE BINDING COMPOUNDS AND RELATED METHODS |
CN107250158B (zh) * | 2014-11-19 | 2022-03-25 | 基因泰克公司 | 抗转铁蛋白受体/抗bace1多特异性抗体和使用方法 |
CN107001473B (zh) * | 2014-11-19 | 2021-07-09 | 豪夫迈·罗氏有限公司 | 抗-运铁蛋白受体抗体及使用方法 |
BR112017024610A2 (pt) * | 2015-06-24 | 2018-07-31 | F. Hoffmann-La Roche Ag | anticorpos para receptor antitransferrina com afinidade especificada |
AR106189A1 (es) * | 2015-10-02 | 2017-12-20 | Hoffmann La Roche | ANTICUERPOS BIESPECÍFICOS CONTRA EL A-b HUMANO Y EL RECEPTOR DE TRANSFERRINA HUMANO Y MÉTODOS DE USO |
US10457717B2 (en) * | 2017-02-17 | 2019-10-29 | Denali Therapeutics Inc. | Engineered polypeptides |
-
2018
- 2018-08-10 PT PT187565312T patent/PT3665192T/pt unknown
- 2018-08-10 CN CN201880063660.0A patent/CN111148757A/zh active Pending
- 2018-08-10 EP EP18843180.3A patent/EP3665194A4/en active Pending
- 2018-08-10 CN CN201880053177.4A patent/CN111094336A/zh active Pending
- 2018-08-10 MD MDE20200637T patent/MD3665192T2/ro unknown
- 2018-08-10 TW TW107128067A patent/TWI821197B/zh active
- 2018-08-10 HR HRP20231118TT patent/HRP20231118T1/hr unknown
- 2018-08-10 SI SI201830986T patent/SI3665192T1/sl unknown
- 2018-08-10 JP JP2020506964A patent/JP7280241B2/ja active Active
- 2018-08-10 DK DK18756531.2T patent/DK3665192T3/da active
- 2018-08-10 PL PL18756531.2T patent/PL3665192T3/pl unknown
- 2018-08-10 ES ES18756531T patent/ES2956062T3/es active Active
- 2018-08-10 WO PCT/US2018/046199 patent/WO2019032955A1/en active Application Filing
- 2018-08-10 HU HUE18756531A patent/HUE063021T2/hu unknown
- 2018-08-10 CA CA3072035A patent/CA3072035A1/en active Pending
- 2018-08-10 WO PCT/US2018/046337 patent/WO2019033046A1/en unknown
- 2018-08-10 RS RS20230817A patent/RS64584B1/sr unknown
- 2018-08-10 JP JP2020507090A patent/JP2020530465A/ja active Pending
- 2018-08-10 CA CA3072051A patent/CA3072051A1/en active Pending
- 2018-08-10 EP EP18756531.2A patent/EP3665192B1/en active Active
- 2018-08-10 LT LTEPPCT/US2018/046199T patent/LT3665192T/lt unknown
- 2018-08-10 FI FIEP18756531.2T patent/FI3665192T3/fi active
-
2020
- 2020-02-05 US US16/782,669 patent/US20200369746A1/en not_active Abandoned
- 2020-02-05 US US16/782,984 patent/US20200289627A1/en not_active Abandoned
-
2023
- 2023-02-08 US US18/166,223 patent/US20230381286A1/en active Pending
- 2023-06-30 JP JP2023107814A patent/JP2023123757A/ja active Pending
- 2023-09-08 US US18/464,025 patent/US20240024432A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
JP7280241B2 (ja) | 2023-05-23 |
US20230381286A1 (en) | 2023-11-30 |
CA3072035A1 (en) | 2019-02-14 |
HRP20231118T1 (hr) | 2023-12-22 |
MD3665192T2 (ro) | 2023-12-31 |
US20200369746A1 (en) | 2020-11-26 |
FI3665192T3 (fi) | 2023-09-28 |
DK3665192T3 (da) | 2023-10-09 |
HUE063021T2 (hu) | 2023-12-28 |
EP3665192B1 (en) | 2023-07-12 |
US20240024432A1 (en) | 2024-01-25 |
WO2019032955A1 (en) | 2019-02-14 |
EP3665194A4 (en) | 2021-07-07 |
JP2020530293A (ja) | 2020-10-22 |
TWI821197B (zh) | 2023-11-11 |
ES2956062T3 (es) | 2023-12-12 |
JP2023123757A (ja) | 2023-09-05 |
JP2020530465A (ja) | 2020-10-22 |
WO2019033046A1 (en) | 2019-02-14 |
EP3665192A1 (en) | 2020-06-17 |
CA3072051A1 (en) | 2019-02-14 |
PL3665192T3 (pl) | 2023-11-27 |
EP3665194A1 (en) | 2020-06-17 |
LT3665192T (lt) | 2023-10-25 |
TW201920278A (zh) | 2019-06-01 |
PT3665192T (pt) | 2023-09-25 |
CN111148757A (zh) | 2020-05-12 |
US20200289627A1 (en) | 2020-09-17 |
RS64584B1 (sr) | 2023-10-31 |
CN111094336A (zh) | 2020-05-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL268660A (en) | Polypeptides that bind to a transgenic transferrin receptor | |
HUE063021T2 (hu) | Mesterségesen elõállított transzferrin receptor-kötõ polipeptidek | |
HK1251480A1 (zh) | Cd3結合多肽 | |
IL272643A (en) | Binders | |
ZA201906358B (en) | Improved antigen binding receptors | |
IL274926A (en) | Pyrazolopyrimidines with activity against respiratory syncytial virus | |
HUE064205T2 (hu) | PSMA kötõ antitest és annak alkalmazásai | |
IL268288A (en) | Binders | |
EP3625300C0 (en) | ADHESIVES | |
IL270969A (en) | Aggrecan-binding immunoglobulins | |
IL270949A (en) | A protease and a polypeptide that binds to O-glycoproteins | |
GB201707139D0 (en) | Polypeptides | |
IL268360A (en) | Engineered concrete binding compound | |
IL269477A (en) | Polypeptides that bind to IL-1R-1 | |
GB201615588D0 (en) | TSLP Binding Proteins | |
GB201702069D0 (en) | Binding polypeptides | |
GB201801959D0 (en) | Binding polypeptides | |
IL266419A (en) | Binding peptides | |
GB201715149D0 (en) | IL-ß binding antibody | |
GB201901704D0 (en) | Binding polypeptides | |
GB201717958D0 (en) | Novel polypeptides | |
GB201713296D0 (en) | Binding agents | |
GB201713298D0 (en) | Binding agents | |
GB201701351D0 (en) | Binding agents | |
GB201618186D0 (en) | Binding members |